Cardio Diagnostics Holdings, Inc. (CDIO): רווח נקי למניה (EPS TTM)

Cardio Diagnostics (CDIO) has achieved a breakthrough in cardiology by identifying heart attack threats through epigenetic blood tests. The current rolling annual EPS value helps filter out market noise when searching for the business inflection point, where -2.53 determines the current status of the parameter. The implementation of AI screening in clinics ensures stable demand for consumables while management optimizes expenses amid limited capital.

Net income per share over 12 months reflects the actual portion of total income attributable to a single security. Investors evaluate capital management efficiency by analyzing the 12-month net income per share snapshot to forecast returns. Growth in this metric confirms the fundamental stability of the business. For Cardio Diagnostics (CDIO), this indicator correlates with the demand for genetic tests. The diversification of diagnostic solutions ensures a steady stream of profit.